EuroPCR in Brief
This article was originally published in The Gray Sheet
New clinical data from St. Jude Medical’s and Boston Scientific’s trials of renal denervation devices to treat hypertension show progress in the development of these novel blood pressure therapies, but both companies remain behind Medtronic. More news from EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.
You may also be interested in...
Data on both new transcatheter aortic valve technologies and established TAVR devices were featured at this year’s EuroPCR meeting in Paris.
Medtronic Renal Denervation System Provides Durable Blood Pressure Benefits In Longest Trial To Date
The latest results from Medtronic’s SYMPLICITY HTN-2 trial show that patients treated for severe hypertension with the company’s Symplicity radio frequency renal denervation system showed a sustained reduction in blood pressure. The firm also announced the start of a renal denervation trial in patients with moderate hypertension.
The company announced plans to reduce annual expenses by $150 to $200 million by reducing up to 1,500 positions through a combination of employee attrition and position reductions. The company also announced that Jeffrey Capello will step down as chief financial officer at the end of the year.